Recent News
FEB 2, 2021
DEC 16, 2020
NOV 24, 2020
NOV 16, 2020
Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19
Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders
Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19
Careers
Abpro offers competitive salaries and generous benefits with the opportunity to learn and grow in an employee-driven culture. We are seeking individuals with infectious enthusiasm, passion, and conviction who will be committed to our core values and mission. If you thrive in an upbeat, energetic, collaborative environment where every individual counts, we are looking for you!